Parents’ intention to vaccinate their 5- to 11-year-old children with the COVID-19 vaccine: rates, predictors and the role of incentives

Author:

Shmueli Liora

Abstract

Abstract Introduction Immediately after Pfizer announced encouraging effectiveness and safety results from their COVID-19 vaccine clinical trials in 5- to 11-year-old children, this study aimed to assess parents’ perceptions and intention to vaccinate their 5-11-year-old children and to determine socio-demographic, health-related, behavioral factors, as well as the role of incentives. Methods A cross-sectional online survey of parents of children between 5 and 11 years of age among the Jewish population in Israel (n = 1,012). The survey was carried out between September 23 and October 4, 2021, at a critical time, immediately after Pfizer’s announcement. Two multivariate regressions were performed to determine predictors of parents’ intention to vaccinate their 5-11-year-old children against COVID-19. Results Overall, 57% of the participants reported that they intend to vaccinate their 5-11-year-old children against COVID-19 in the winter of 2022. 27% noted that they would vaccinate their 5-11-year-old children immediately; 26% within three months; and 24% within more than three months. Perceived susceptibility, benefits, barriers and cues to action, as well as two incentives - vaccine availability and receiving a “Green Pass” - were all significant predictors. However, Incentives such as monetary rewards or monetary penalties did not increase the probability of parents’ intention to vaccinate their children. Parental concerns centered around the safety of the vaccine, fear of severe side effects, and fear that clinical trials and the authorization process were carried out too quickly. Conclusion This study provides data on the role of incentives in vaccinating 5-11-year-old children, how soon they intend to do so, and the predictors of those intentions, which is essential knowledge for health policy makers planning vaccination campaigns.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health

Reference35 articles.

1. Children. and COVID-19: State-Level Data Report, (n.d.). http://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/ (accessed October 10, 2021).

2. Preliminary Evidence on Long COVID in children | medRxiv., (n.d.). https://www.medrxiv.org/content/https://doi.org/10.1101/2021.01.23.21250375v1.full (accessed October 23, 2021).

3. Kamidani S, Rostad CA, Anderson EJ. COVID-19 vaccine development: a pediatric perspective. Curr Opin Pediatr. 2021;33:144–51. https://doi.org/10.1097/MOP.0000000000000978.

4. Dooling K. Use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥ 16 years: recommendations of the Advisory Committee on Immunization Practices — United States, September 2021, MMWR Morb. Mortal Wkly Rep. 2021;70. https://doi.org/10.15585/mmwr.mm7038e2.

5. O. of the Commissioner, Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic, FDA. (2021). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use (accessed September 29, 2021).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3